CACNA1C and early-onset autosomal dominant Alzheimer disease: In this review, we summarize the post-translational modifications of Cav1.2 and its role in neurodegenerative diseases, and further discuss the potential of Cav1.2 as a drug target for Alzheimer’s disease (AD) and Parkinson’s disease (PD).